(Translation) UAC.CS/003/2020 February 27, 2020 Subject: Explanation of the operating results for the year period ended December 31, 2019 To: President The Stock Exchange of Thailand Attachment

MDA Q3_2017 (Eng.) November 8, 2017 Subject : Interim Management Discussion and Analysis of Q3/2017 Attention : President of The Stock Exchange of Thailand We attach herewith the financial statements

Transfer of Fame Line Company Limited (Subsidiary) 3. To appoint the Company’s Executives Attention : The President of the Stock Exchange of Thailand Far East DDB Public Company Limited (“Company”) would

S&P MD&A Q2_2019-Eng Ref. POL. 085/2019 August 8th 2019 Re: Clarification of the Performance of S & P Syndicate Public Company Limited Dear The President The Stock Exchange of Thailand S & P

Microsoft Word - MDA Q219 EN August 14, 2019 To President The Stock Exchange of Thailand Subject Notification on the difference of revenue from sales and net profit YOY by more than 20 percent

and analysis for the period ended June 30, 2018 To Director and Manager of the Stock Exchange of Thailand Referring to the submission of the reviewed financial statements for quarter 2/2018 of Wiik

1/5 Ref. 4/2019 January 11, 2019 Subject : The acquisition of investment in Ramkhamhaeng Hospital PCL. To : Director and Manager The Stock Exchange of Thailand The Board of Directors Meeting

Page 1 of 4 No. RJH – SET 7/2020 11 May 2020 Subject : Management’s Discussion and Analysis for the First Quarter of 2020 To : The President The Stock Exchange of Thailand Rajthanee Hospital Public

August 11, 2020 Subject: Management’s Discussion and Analysis for the second Quarter of 2020 To: The President The Stock Exchange of Thailand (SET) DOD Biotech Public Company Limited and its subsidiaries

Exchange of Thailand Dimet (Siam) Public Company Limited “company” would like to notify on qualified opinion from auditor as shown in Noted to Financial Statement due to authorized directors of ASIAN